{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T10:40:17Z","timestamp":1736937617893,"version":"3.33.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ad.2024.10.002","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T19:01:04Z","timestamp":1728500464000},"page":"T113-T117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["[Translated article] Real-World Experience of Secukinumab Dose Optimization in Moderate-to-Severe Psoriasis. Retrospective, Single-Center Series of 11-Patients"],"prefix":"10.1016","volume":"116","author":[{"given":"\u00c1.","family":"Aguado V\u00e1zquez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.J.","family":"Melgosa Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Alonso D\u00edez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mateu Puchades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2024.10.002_bib0055","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2024.10.002_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-015-0092-3","article-title":"A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis","volume":"6","author":"Campa","year":"2016","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ad.2024.10.002_bib0065","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ad.2021.10.003","article-title":"Parte 1. \u00abConceptos y manejo general de la psoriasis con terapia biol\u00f3gica\u00bb","volume":"113","author":"Carrascosa","year":"2022","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2024.10.002_bib0070","doi-asserted-by":"crossref","first-page":"14134","DOI":"10.1111\/dth.14134","article-title":"Reduced doses of biological therapies in psoriasis may increase efficiency without decreasing drug survival","volume":"33","author":"Llamas-Velasco","year":"2020","journal-title":"Dermatologic therapy"},{"key":"10.1016\/j.ad.2024.10.002_bib0075","first-page":"569","article-title":"Dose modification in biologic therapy for moderate to severe psoriasis: a descriptive analysis in a clinical practice setting","volume":"106","author":"Baniandres","year":"2015","journal-title":"Actas DermoSifiliograficas"},{"key":"10.1016\/j.ad.2024.10.002_bib0080","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3109\/09546634.2015.1034070","article-title":"Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice","volume":"26","author":"Carrascosa","year":"2015","journal-title":"The Journal of dermatological treatment"},{"key":"10.1016\/j.ad.2024.10.002_bib0085","article-title":"National consensus on biologic dose reduction in psoriasis: a modified eDelphi procedure","author":"van der Schoot","year":"2022","journal-title":"The Journal of dermatological treatment, 2154570. Advance online publication."},{"key":"10.1016\/j.ad.2024.10.002_bib0090","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1186\/s13063-021-05681-z","article-title":"Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study","volume":"22","author":"Van der Schoot","year":"2021","journal-title":"Trials."},{"key":"10.1016\/j.ad.2024.10.002_bib0095","unstructured":"Cosentyx [prescribing information]. East Hanover, NJ: Novartis Pharmaceutical Corporation, 2017."},{"key":"10.1016\/j.ad.2024.10.002_bib0100","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjd.18143","article-title":"Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol."}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731024007592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731024007592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T08:55:37Z","timestamp":1736844937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731024007592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0001731024007592"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2024.10.002","relation":{},"ISSN":["0001-7310"],"issn-type":[{"type":"print","value":"0001-7310"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Real-World Experience of Secukinumab Dose Optimization in Moderate-to-Severe Psoriasis. Retrospective, Single-Center Series of 11-Patients","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2024.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2023.08.021","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}